Sai Duriseti, MD, PhD

Assistant Professor, Radiation Oncology

Member, Cancer Molecular Imaging, Nanotechnology and Theranostics

Languages

English

Education

Internship

Internal Medicine, University of Colorado, Aurora, CO, 2017

Degrees

MD, University of California, San Francisco, 2016

PhD, University of California, San Francisco, 2012

BS, The Johns Hopkins University, Baltimore, MD, 2005

Residency

Radiation Oncology, Washington University in St. Louis, MO, 2021

Contact Information

Email

[email protected]

Phone

(310) 478-3711 x46733

Scientific Interests

Dr. Duriseti is interested in the interplay between ablative radiotherapy and the immune system. Specifically, he is interested in the discovery and development of targeted agents that mimic the anti-tumor response , and other protein-based agents, for therapeutic and diagnostic purposes in oncology.

Highlighted Publications

Schiff J, Spraker M, Duriseti S, et al. Case report of tumor lysis syndrome after treatment with Lattice SBRT. Advances in Radiation Oncology, 2021.

Duriseti S, et al. Lattice stereotactic body radiotherapy for large tumors. Advances in Radiation Oncology, 2021.

Kavanaugh J, Duriseti S, et al. LITE SABR M1: Planning design and dosimetric endpoints for a Phase I trial of Lattice SBRT. Radiotherapy and Oncology, 2021.

Duriseti S, et al. LITE SABR M1: a phase I trial of Lattice SBRT for large tumors. Radiotherapy and Oncology, 2021.

Orukari I, Perkins S, Zhao T, Huang J, Caruthers DF, Duriseti S. Brainstem toxicity in pediatric patients treated with protons using a single-vault synchrocyclotron system. International Journal of Particle Therapy, 2022.